Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$134 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-65 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
1.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.6
Face value
--
Shares outstanding
62,011,800
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
| 27.8 | 1.9 | 16.8 | -31.9 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
2.2 | 134.0 | 0.0 | -96.3 | -- | -57.4 | -- | 0.4 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in... Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc. Read more
Founder & Director
Dr. Uri A. Lopatin M.D.
Founder & Director
Dr. Uri A. Lopatin M.D.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Pardes Biosciences Inc (PRDS) is $2.16 (NASDAQ) as of 08-Sep-2023 09:30 EDT. Pardes Biosciences Inc (PRDS) has given a return of -31.86% in the last 1 years.
Since, TTM earnings of Pardes Biosciences Inc (PRDS) is negative, P/E ratio is not available.
The P/B ratio of Pardes Biosciences Inc (PRDS) is 0.37 times as on 08-Sep-2023, a 91 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.07
|
0.56
|
|
2021
|
-26.49
|
3.83
|
|
2020
|
--
|
--
|
|
2022
|
-1.07
|
0.56
|
|
2021
|
-26.49
|
3.83
|
The 52-week high and low of Pardes Biosciences Inc (PRDS) are Rs -- and Rs -- as of 03-Apr-2026.
Pardes Biosciences Inc (PRDS) has a market capitalisation of $ 134 Mln as on 08-Sep-2023. As per SEBI classification, it is a company.
Before investing in Pardes Biosciences Inc (PRDS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.